Dr Marie-Louise Zeissler
Peninsula Medical School (Faculty of Health)
I am a molecular biologist by training with four years of experience in researching cannabinoids as neuroprotective agents in a cell culture model of Parkinson’s disease and more than 9 years of experience in laboratory based research. In 2019, I joined the Applied Parkinson's Research Group to support efforts in developing a multi-arm multi-stage (MAMS) trial for Parkinson's disease.
2012 PhD - Peninsula School of Medicine and Dentistry, Plymouth, UK
2009 MSci Biology – University of Bath, UK
As part of the Applied Parkinson's Research Group led by Dr Camille Carroll and in collaboration with the Cure Parkinson's Trust I am exploring innovations in the design of trials aimed at investigating therapies to slow or delay the progression of Parkinson's disease. In particular we are looking to develop a multi-arm multi-stage (MAMS) trial platform for Parkinson's and my current research projects are centered around supporting this aim. To find out more about MAMS, please follow this link which will lead you to "The Science of Parkinson's" web-page by Simon Stott (Cure Parkinson's) who explains all about MAMS in his article "MAMS the word"
Key publications are highlightedJournals
Zeissler, M.-L., Li, V., Parmar, M. K. B., & Carroll, C. B. (2020). Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer. Journal of Parkinson’s Disease 10(2).
Saarinen NVV, Laiho JE, Richardson SJ, Zeissler M, Stone VM, Marjomäki V, Kantoluoto T, Horwitz MS, Sioofy-Khojine A, Honkimaa A, Hankaniemi MM, Flodström-Tullberg M, Hyöty H, Hytönen VP, Laitinen OH (2018) A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses. Scientific Reports 8(1).
Richardson SJ, Rodriguez-Calvo T, Gerling IC, Mathews CE, Kaddis JS, Russell MA, Zeissler M, Leete P, Krogvold L, Dahl-Jørgensen K, von Herrath M, Pugliese A, Atkinson MA, Morgan NG (2016) Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59(11).
Zeissler ML, Eastwood J, McCorry K, Hanemann CO, Zajicek JP, Carroll CB (2016) Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. Oncotarget.
Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP (2012) Δ 9 -tetrahydrocannabinol (Δ 9 -THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson’s disease. Neuropathology and Applied Neurobiology 38(6)
Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE, Hanemann CO (2011) Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson’s disease. Neurochemistry International 59(1).